A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

In recent years, blockbuster glucagon-like peptide 1 receptor agonist (GLP-1RA) therapies like Eli Lilly’s Zepbound ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...